Longevity Technology interviews Frequency Tx' CSO about activating innate progenitor cells
Longevity Technology - 01-Nov-2022Cells are already in the right place, just need the right kick to help repair the body when needed
Chris Loose
Co-founder and Chief Scientific Officer at Frequency Therapeutics
Chris has served as Frequency’s Chief Scientific Officer since co-founding the company in 2014. Before joining Frequency, he served as Chief Technology Officer for Semprus BioSciences, a company he also co-founded and was acquired by Teleflex in 2012.
He is currently the Executive Director of Yale University’s Center for Biomedical and Interventional Technology (CBIT), and Associate Adjunct Professor of Urology in the Yale School of Medicine.
Chris holds a Ph.D. in Chemical Engineering from MIT, where he was a Hertz Fellow and studied under Robert Langer, Sc.D. Previously, he earned a B.S.E in Chemical Engineering summa cum laude from Princeton University.
Visit website: https://www.frequencytx.com/people/chris-loose-phd/
See also: 
Korro Bio
- RNA editing, leveraging natural processes common to all multi-cellular organisms, merged with Frequency Therapeutics
Details last updated 02-Nov-2022
Chris Loose News
Topics mentioned on this page:
Regenerative Medicine
